/ /

psoriasis

Will new autoimmune drugs address cost concerns?Find out what’s in the drug pipeline for autoimmune disease.
First-ever U.S. psoriasis treatment goalsThe National Psoriasis Foundation has recently published psoriasis treatment goals, which will help physicians and patients discuss treatment options and set expectations for outcomes.
December Clinical Considerations for NPs, PAsIn this month's Clinical Considerations, we take a look at AD and bullying, whether or not derms are doing enough for psoriasis patients, and the potential of Epicutaneous immunotherapy.
Pearls to optimize safety, success with biologicsOne dermatologist describes his considerations for choosing a biologic to treat a patient with moderate-to-severe psoriasis, baseline assessments, and follow-up approach.
Advances in pediatric inflammatory skin diseaseExciting research is likely to change treatment for children. Dr. Eichenfield discusses advancements in treating this population.
Infant’s disseminated rash is twice misdiagnosedA frustrated mother carries her 2-month-old son into the office for evaluation of a diffuse bright red rash with dramatic hypopigmentation. Scalp, neck, axillary, and diaper areas are involved.
Integrating pharmacy benefit, medical benefit cuts costsHere’s how one non-profit health plan harnessed the power of medical and pharmacy data to rein in drug costs.
FDA approves etanercept for pediatric psoriasisThe US Food and Drug Administration (FDA) approval of etanercept for treatment of children with moderate to severe plaque psoriasis will revolutionize the management of psoriasis in children.
More evidence links psoriasis to depression
More evidence links psoriasis to depressionA recent study provides more evidence that patients with psoriasis–even mild cases–face a higher risk of major depression, a finding that could lead dermatologists to alert patients with the condition and even screen them for mental health issues.
Novartis announces new Cosentyx data in psoriasis treatment, including long-term studyResearchers presented new data on the use of the fully human IL-17A inhibitor Cosentyx (secukinumab, Novartis) in moderate-to-severe psoriasis, at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, September 28 through October 2, 2016.